Beijing-based biotech company EdiGene Inc – that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions – has raised about $15 million in a pre-Series B financing round led by Lilly Asia Ventures (LAV) a venture capital firm from Shanghai, according to an announcement.
Beijing-based investment firm Huagai Capital also participated in this round.
